Log in
Enquire now
‌

US Patent 11060715 Ex vivo proliferation of epithelial cells

Patent 11060715 was granted and assigned to Propagenix Inc. on July, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Propagenix Inc.
Propagenix Inc.
Current Assignee
Propagenix Inc.
Propagenix Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11060715
Date of Patent
July 13, 2021
Patent Application Number
16525999
Date Filed
July 30, 2019
Patent Citations
‌
US Patent 10711250 Ex vivo proliferation of epithelial cells
‌
US Patent 10066201 Ex vivo proliferation of epithelial cells
‌
US Patent 10100285 Ex vivo proliferation of epithelial cells
‌
US Patent 10119121 Ex vivo proliferation of epithelial cells
‌
US Patent 10514163 Ex vivo proliferation of epithelial cells
‌
US Patent 10711251 Ex vivo proliferation of epithelial cells
Patent Citations Received
‌
US Patent 11680246 Ex vivo proliferation of epithelial cells
0
Patent Primary Examiner
‌
Haissa Philogene
Patent abstract

The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11060715 Ex vivo proliferation of epithelial cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.